Susceptibility of CD24+ ovarian cancer cells to anti-cancer drugs and natural killer cells

Biochemical and Biophysical Research Communications

Volumn 427, Issue 2, 2012, Pages 373-378

  Koh, Jiae ^a   Lee, Saet byul ^a   Park, Hyunju ^a   Lee, Hyo Jun ^a   Cho, Nam Hoon ^a   Kim, Jongsun ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

CD24; Drug resistance; Immunotherapy; Natural killer cell; Ovarian cancer cell

Indexed keywords

CD24 ANTIGEN; CISPLATIN; DOXORUBICIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NATURAL KILLER CELL RECEPTOR NKG2D;

ARTICLE; CANCER CELL; CELL SURFACE; CYTOLYSIS; CYTOTOXICITY; DOWN REGULATION; DRUG RESISTANCE; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN CELL; METASTASIS; NATURAL KILLER CELL; NORMAL HUMAN; OVARY CANCER; PRIORITY JOURNAL; TUMOR RECURRENCE; UPREGULATION;

ANTIGENS, CD24; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SEPARATION; CISPLATIN; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOTHERAPY; KILLER CELLS, NATURAL; LIGANDS; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; OVARIAN NEOPLASMS;

EID: 84867846693     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.09.067     Document Type: Article

References (25)

1. Cerwenka A., Lanier L.L. Natural killer cells, viruses and cancer. Nat. Rev. Immunol. 2001, 1:41-49.
2. Yokoyama W.M., Kim S., French A.R. The dynamic life of natural killer cells. Annu. Rev. Immunol. 2004, 22:405-429.
3. Wiltrout R.H., Mathieson B.J., Talmadge J.E., Reynolds C.W., Zhang S.R., Herberman R.B., Ortaldo J.R. Augmentation of organ-associated natural killer activity by biological response modifiers. Isolation and characterization of large granular lymphocytes from the liver. J. Exp. Med. 1984, 160:1431-1449.
4. Voskoboinik I., Dunstone M.A., Baran K., Whisstock J.C., Trapani J.A. Perforin: structure, function, and role in human immunopathology. Immunol. Rev. 2010, 235:35-54.
5. Cullen S.P., Brunet M., Martin S.J. Granzymes in cancer and immunity. Cell Death Differ. 2010, 17:616-623.
6. Yokoyama W.M. Recognition structures on natural killer cells. Curr. Opin. Immunol. 1993, 5:67-73.
7. Lanier L.L. NK cell receptors. Annu. Rev. Immunol. 1998, 16:359-393.
8. Sun J.C., Lanier L.L. Cutting edge: viral infection breaks NK cell tolerance to " missing self". J. Immunol. 2008, 181:7453-7457.
9. Monteiro J., Fodde R. Cancer stemness and metastasis: therapeutic consequences and perspectives. Eur. J. Cancer 2010, 46:1198-1203.
10. Reya T., Morrison S.J., Clarke M.F., Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature 2001, 414:105-111.
11. Stingl J., Caldas C. Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis. Nat. Rev. Cancer 2007, 7:791-799.
12. Bomken S., Fiser K., Heidenreich O., Vormoor J. Understanding the cancer stem cell. Br. J. Cancer 2010, 103:439-445.
13. Bonnet D., Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 1997, 3:730-737.
14. Huntly B.J., Gilliland D.G. Leukaemia stem cells and the evolution of cancer-stem-cell research. Nat. Rev. Cancer 2005, 5:311-321.
15. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA 2003, 100:3983-3988.
16. + cells from hierarchically organized ovarian cancer are enriched in cancer stem cells. Oncogene 2010, 29:2672-2680.
17. Dean M., Fojo T., Bates S. Tumour stem cells and drug resistance. Nat. Rev. Cancer 2005, 5:275-284.
18. Dean M., Fojo T., Bates S. Tumour stem cells and drug resistance. Nat. Rev. Cancer 2005, 5:275-284.
19. Castriconi R., Daga A., Dondero A., Zona G., Poliani P.L., Melotti A., Griffero F., Marubbi D., Spaziante R., Bellora F., Moretta L., Moretta A., Corte G., Bottino C. NK cells recognize and kill human glioblastoma cells with stem cell-like properties. J. Immunol. 2009, 182:3530-3539.
20. Alvarado C.S., Findley H.W., Chan W.C., Hnath R.S., Abdel-Mageed A., Pais R.C., Kutner M.H., Ragab A.H. Natural killer cells in children with malignant solid tumors. Effect of recombinant interferon-alpha and interleukin-2 on natural killer cell function against tumor cell lines. Cancer 1989, 63:83-89.
21. Itoh K., Platsoucas C.D., Balch C.M. Monocyte- and natural killer cell-mediated spontaneous cytotoxicity against human noncultured solid tumor cells. Cell Immunol. 1987, 108:495-500.
22. Smyth M.J., Swann J., Cretney E., Zerafa N., Yokoyama W.M., Hayakawa Y. NKG2D function protects the host from tumor initiation. J. Exp. Med. 2005, 202:583-588.
23. Ogasawara K., Benjamin J., Takaki R., Phillips J.H., Lanier L.L. Function of NKG2D in natural killer cell-mediated rejection of mouse bone marrow grafts. Nat. Immunol. 2005, 6:938-945.
24. Zhang S., Balch C., Chan M.W., Lai H.C., Matei D., Schilder J.M., Yan P.S., Huang T.H., Nephew K.P. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res. 2008, 68:4311-4320.
25. Curley M.D., Therrien V.A., Cummings C.L., Sergent P.A., Koulouris C.R., Friel A.M., Roberts D.J., Seiden M.V., Scadden D.T., Rueda B.R., Foster R. CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. Stem Cells 2009, 27:2875-2883.